Tutar Lütfi, Tutar Esen, Özgür Aykut, Tutar Yusuf
Faculty of Science and Letters, Department of Biology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.
Graduate School of Natural and Applied Sciences, Department of Bioengineering and Sciences, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.
Drug Dev Res. 2015 Nov;76(7):382-8. doi: 10.1002/ddr.21273. Epub 2015 Aug 26.
Preclinical Research The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 18 - 24 nucleotides long, miRNAs can up-regulate or down-regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression profiles of miRNAs with biomarker potential can be used for the classification, diagnosis, therapeutic treatment, and prognosis of different cancer types. miRNA mimics and miRNA antagonists are the two main approaches to miRNA-based cancer therapies that respectively inhibit oncomirs or restore the expression of tumor suppressive miRNAs. This review serves to provide some general insight into miRNA biogenesis, cancer related miRNAs, and miRNA therapeutics.
临床前研究 微小RNA(miRNA)的发现及其与癌症的关联开启了癌症治疗的新纪元。miRNA长度约为18 - 24个核苷酸,可在多种癌症类型中上调或下调基因表达,分别被归类为癌基因(致癌miRNA)或肿瘤抑制因子。具有生物标志物潜力的miRNA表达谱可用于不同癌症类型的分类、诊断、治疗和预后评估。miRNA模拟物和miRNA拮抗剂是基于miRNA的癌症治疗的两种主要方法,它们分别抑制致癌miRNA或恢复肿瘤抑制性miRNA的表达。本综述旨在提供一些关于miRNA生物发生、癌症相关miRNA和miRNA治疗的一般见解。